Plan robustness evaluation strategies in whole-pelvic proton therapy for high-risk prostate cancer patients within a randomised clinical trial.
Sofie TilbækStine Elleberg PetersenLiliana StolarczykAnne VestergaardHeidi S RøndeLise N BentzenJimmi SøndergaardMorten HøyerLudvig Paul MurenPublished in: Acta oncologica (Stockholm, Sweden) (2023)
The PRE strategy predicted the DRE scenarios for CTVp and rectum. CTVe, bladder, and bowel showed more complex anatomical variations than simulated by the PRE isocenter shift. Both original and recalculated nominal treatment plans showed robust treatment delivery in terms of target coverage.
Keyphrases
- prognostic factors
- clinical trial
- prostate cancer
- open label
- spinal cord injury
- study protocol
- randomized controlled trial
- double blind
- end stage renal disease
- chronic kidney disease
- climate change
- radical prostatectomy
- small cell lung cancer
- rectal cancer
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- patient reported outcomes
- affordable care act